
TRANSMITTAL FORM

Application Serial Number	09/248,964	70 3
Filing Date	February 12, 1999	OCT 2 1 1999
First Named Inventor	Wucherpfennig et al.	E AS
Group Art Unit	1646	TA TRADEMARK
Examiner Name	Not yet assigned	
Attorney Docket No.	HAR-005	

amunication to Board	
Appeal Communication to Board of Patent Appeals and Interferences	
nmunication to Group tice, Brief, Reply Brief)	
er	
eipt Postcard	
of First Class Mailing F.R. 1.8	
Enclosure(s) ntify below)	
ugy velowy	
y submitted, Bresnahan Applicants vitz & Thibeault, LLP Tower treet	
F. Errati	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Wucherpfennig et al.

RECEIVED

SERIAL NO.:

09/248,964

GROUP NO.:

1646

OCT 2 2 1999

FILING DATE:

TITLE:

February 12, 1999 EXAMINER: Not yet assigned
TEGH CENTER 1600/2900
MONOVALENT, MULTIVALENT, AND MULTIMERIC MHC

BINDING DOMAIN FUSION PROTEINS AND CONJUGATES,

AND USES THEREFOR

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this 14th day of October, 1999.

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith is/are:

Transmittal Form (1 pg.); Information Disclosure Statement (2 pgs.); PTO Form 1449 (7 pgs.); copies of references cited A1-A9, B1-B9, and C1-C77; and a return postcard.

BRESNAHA6615/8.A842071-1

PATENT Attorney Docket No. HAR-005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Wucherpfennig et al.

SERIAL NO.:

09/248,964

GROUP NO.:

1646

FILING DATE:

February 12, 1999

EXAMINER:

Not yet assigned

TITLE:

MONOVALENT, MULTIVALENT, AND MULTIMERIC MHC

BINDING DOMAIN FUSION PROTEINS AND CONJUGATES,

AND USES THEREFOR

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. §1.97, Applicants hereby make of record the references listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the references are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

\boxtimes	(1)	within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
	(2)	after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and
		the requisite Statement is below, OR
		the requisite fee under Rule 1.17(p), namely \$240.00, is included herein, or
	(3)	after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, AND
		Applicant hereby Petitions the Commissioner to accept and consider the attached Information Disclosure Statement. AND



Information Disclosure Stateme Serial No.: 09/248,964

Page 2 of 2

	OCT 2 1 1999	•
the requisite Statement is below, AND	PATE STATE	1
the requisite petition fee due under Rule 1.17(i)(I), namely \$130.00 is incl	uded herein.	

It is respectfully requested that each of the references shown on the attached Form PTO-1449 be made of record in this application.

STATEMENT

As required under §1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- 1. [E]ach item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application **not more than** three months prior to the filing date of the Information Disclosure Statement; or
- 2. [N]o item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 20-0531. Any overpayments should be credited to said Deposit Account.

Date: October 14, 1999 Reg. No. P-44,559

Tel. No.: (617) 248-7103 Fax No.: (617) 248-7100

BRESNAHA6615/8.842028

Respectfully submitted,

Maureen A Bresnahan Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110

EXAMINER

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999 GROUP: 1646

			U.S	. PATENT	DOCUM	ENTS				
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME			CLASS	SUB CLASS	1	ING DATE IF PROPRIATE
	Al	5,928,647	07/27/99	Rock			424	196.11	01/1	10/94
	A2	5,820,866	10/13/98	Kappler et	al.		424	192.1	03/0)4/94
	A3	5,714,166	02/03/98	Tomalia et	al.		424	486	03/0	7/95
	A4	5,541,087	07/30/96	Lo et al.			435	697	09/1	4/94
	A5	5,338,532	08/16/94	Tomalia et	al.		424	1.49	02/1	3/91
	A6	5,314,813	05/24/94	Peterson et	al.		435	172.3	02/1	9/92
	A7	5,284,935	02/08/94	Clark et al.			530	403	12/2	28/90
	A8	5,260,422	11/09/93	Clark et al.			530	403	04/2	23/91
	A9	5,130,297	07/14/92	Sharma et d	ıl.		514	8	08/3	30/90
			FOREI	GN PATEN	T DOCU	MENTS			•	
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTR/ ONLY	ACT	ENGLISH LANG Y/N
	B1	WO 99/09064	02/25/99	PCT			11/04/97			Y
	B2	WO 98/06749	02/19/98	PCT			08/15/97			Y
	В3	WO 98/03552	01/29/98	PCT			07/15/97			Y
	B4	WO 97/44667	11/27/97	PCT			05/21/97			
"	B5	WO 97/35991	10/02/97	PCT			03/28/97			Y
	В6	WO 96/04314	02/15/96	PCT			07/31/95			Y
	В7	WO 94/15635	07/21/94	PCT						
	В8	WO 93/10220	05/27/93	PCT			11/18/92			Y
	В9	0 393 707 A2	10/24/90	EP			04/20/90			Y

DATE CONSIDERED

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999

GROUP: 1646

REPORT TRADENT

		OTHER ART, JOURNAL ARTICLES, ETC.					
EXAM. INIT.	ОТНЕ	R DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	C1	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes" Science, 274:94-96 (1996)					
	C2	Angel et al., "Oncogene jun encodes a sequence-specific trans-activator similar to AP-1," Nature, 332:166-171 (1988)					
	C3	Avva et al., "In Vivo and In Vitro Formation and Dissociation of HLA-DR Complexes with Invariant Chain-Derived Peptides," Immunity, 1:763-774 (1994)					
	C4	Bell, T.W., "Molecular Trees: A New Branch of Chemistry," Science, 271(5252):1077-8 (1996)					
	C5	Bodmer et al., "Nomenclature for factors of the HLA system, 1995," Tissue Antigens, 46:1-18 (1995)					
	C6	Borman, S., "Technique gets peptides into living cells," C&EN, 27-28 (July 10, 1995)					
	C7	Bradley, D., "Dendrimers Display Liquid Crystal Talents," Science, 270:22 (1995)					
	C8	Brake, A.J., Alpha-Factor Leader-Directed Secretion of Heterologous Proteins from Yeast," Methods in Enzymology, "185:408-421 (1990)					
	C9	Brown et al., "Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1," Nature, 364:33-39 (1993)					
	C10	Biochemical Society Transactions, 20:322S (1992)					
	C11	to expression of and T-cell receptor extracellular segments" <i>Proc. Nati. acaa. Sci.</i> , USA 31.11408					
	C12	HLA-DQ8," International Immunology, 6(11):1639-1649 (1994)					
	C13	Alleles," J. Exp. Med., 178:27-47 (1993)					
	C14	Claus et al., "Are soluble monocyte-derived HLA class II molecules candidates for immunosuppressive activity?," Immunology Letters, 26(3):203-210 (1990)					
<u> </u>	INER	DATE CONSIDERED					

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999 GROUP: 1646

		OTHER ART, JOURN	IAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)				
	C15		ture of a class I major histocompatibility complex molecule Proc. Natl. Acad. Sci. USA, 92:1218-1221 (1995)		
	C16	Cosson et al., "Role of Transmembrane Do Science, 258:659-662 (1992)	omain Interactions in the assembly of Class II MHC Molecules		
	C17	Cregg et al., "High-Level Expression and I Methylotrophic Yeast, Pichia Pastoris," Bi	Efficient Assembly of Hepatitis B Surface Antigen in the o/Technology, 5:479-485 (1987)		
	C18	Dagani, R., "Chemists Explore Potential of 30-38 (June 3, 1996)	Dendritic Macromolecules as Functional Materials," C&EN,		
	C19	DeSimone, J.M., "Branching Out into New	Polymer Markets," Science, 269:1060-1062 (1995)		
	C20 Ferré-D'Amaré et al., "Recognition by Max of its cognate DNA through a dimeric b/HLH/Z doma Nature, 363:38-45 (1993)				
	C21	Fréchet, J.M.J., "Functional Polymers and Interfacial Energy," <i>Science</i> , 263:1710-171	Dendrimers: Reactivity, Molecular Architecture, and 5 (1994)		
	C22	Fréchet <i>et al.</i> , "Self-Condensing Vinyl Poly 269:1080-1083 (1995)	merization: An Approach to Dendritic Materials," Science,		
	C23 Freemantle, M., "Potential Trigger for Dendrimer Switch," C&EN, p. 30 (May 26, 1997)				
	C24 Galliot, C., "Regioselective Stepwise Growth of Dendrimer Units in the Internal Voids of a Main Dendrimer," Science, 277:1981-1984 (1997)				
··-	C25 Grégoire et al., "Engineered secreted T-cell receptor αβ heterodimers," Proc. Natl. Acad. Sci. USA 88:8077-8081 (1991)				
	 C26 Hammer et al., "Analysis of MHC Class II Peptide Interaction with M13 Peptide Display Libraries," Journal of Cellular Biochemistry, Suppl. 17C, p. 215 (1993) C27 Hu et al., "Sequence Requirements for Coiled-Coils: Analysis with λ Repressor-GCN4 Leucine Zippe Fusions," Science, 250:1400-1403 (1990) 				
- · · - · · · · · · · · · · · · · · · ·	C28	Hudson et al., "Direct Visualization of Indi Science, 278:449-452 (1997)	vidual Cylindrical and Spherical Supramolecular Dendrimers,		
EXAMIN	ER		DATE CONSIDERED		

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999 GROUP: 1646

		OTHER ART, JOURN	IAL ARTICLES, ETC.	
EXAM. INIT.	ОТН	ER DOCUMENTS: (Including Author, Ti	tle, Date, Relevant Pages, Place of Publication)	
	C29	Jansen et al., Encapsulation of Guest Molec	cules into a Dendritic Box," Science, 266:1226-1230 (1994)	
	C30	Jiang <i>et al.</i> , "Photoisomerization in dendrir 388(31):454-456 (1997)	ners by harvesting of low-energy photons," Nature,	
	C31	Jones, E.V., "MHC class I and class II stru	actures," Curr. Opin. Immunol, 9(1):75-79 (1997)	
	C32	Kalandadze et al., "Expression of Recombi Chemistry, 271(33):20156-20162 (1996)	nant HLA-DR2 Molecules," The Journal of Biological	
	C33	Kozono et al., "Production of soluble MHC Letters to Nature, 369:151-154 (1994)	C class II proteins with covalently bound single peptides,"	
	C34		cterize HLA-DLQ Interactions with a Diabetes-Associated boxylase," <i>The Journal of Immunology</i> , 156(6):2171-2177	
C35 Kwok et al., "HLA-DQB1 Codon 57 is Critical for Peptide Binding and Recognition," Jour Experimental Medicine, 183(3):1253-1258 (1996)				
	C36 Heard, R., "HLA and autoimmune disease," HLA and Disease, 1994 Academic Press Ltd. p			
	C37 Lin et al., "Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic F Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence," The Journal Biological Chemistry, 270(24):14255-14258 (1995)			
	C38 Madden, D.R., "The Three-Dimensional Structure of Peptide-MHC Complexes," Annu. Rev. Im. 13:587-622 (1995)			
	C39	Marsh et al., "HLA Class II region nucleot	ide sequences, 1995, Tissue Antigens, 45:258-280 (1995)	
	C40 Marsh, S.G.E., "Nomenclature for factors of the HLA system, update June 1995," Tissue Antigor 46:142-143 (1995) C41 Mottershead et al., "Direct Binding of the Mtv7 superantigen (Mls-1) to Soluble MHC Class II Molecules," Immunity, 2:149-154 (1995)			
	C42	Nag et al., "Functionally Active Recombinant and Chain-Peptide Complexes of Human Major Histocompatibility Class II Molecules" <i>The Journal of Biological Chemistry</i> , 271(17): 10413-10417 (1996)		
EXAMIN	ER		DATE CONSIDERED	

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999 GROUP: 1646

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)				
	C43 Nag et al., "In Vitro Maximum Binding of Antigenic Peptides to Murine MHC Class II Molecules do not Always Take Place at the Acidic pH of the In Vivo Endosomal Compartment," The Journal of Immunology, 148(2):369-372 (1992)				
	C44	Nicolle et al., "Specific Tolerance to an Acetylcholine Receptor Epitope Induced in Vitro in Myasthenia Gravis CD4 ⁺ Lymphocytes by Soluble Major Histocompatibility Complex Class II-Peptide Complexes," J. Clin. Invest., 93:1361-1369 (1994)			
	C45	Ohnishi, K., "Domain Structures and Molecular Evolution of Class I and Class II Major Histocompatibility Gene Complex (MHC) Products Deduced from Amino Acid and Nucleotide Sequence Homologies," Origins of Life, 14:707-715 (1984)			
	C46	O'Shea et al., "Preferential Heterodimer Formation by Isolated Leucine Zippers from Fos and Jun," Science, 245:646-648 (1989)			
	C47	O'Shea et al., "X-ray Structure of the GCN4 Leucine Zipper, a Two-stranded, Parallel Coiled Coil," Science, 254:539-544 (1991)			
	C48	Pack et al., "Miniantibodies: Use of Amphipathic Helices to Produce Functional, Flexibly Linked Dimeric F. Fragments with High Avidity in Escherichia coli," Biochemistry, 31(6):1579-1584 (1992)			
	C49	Roberts et al., "Preliminary biological evaluation of polyamidoamine (PAMAM)Starburst TM dendrimers, Journal of Biomedical Materials Research, 30:53-65 (1996)			
	C50	Rolland et al., "New Macromolecular Carriers for Drugs. I. Preparation and Characterization of Poly (oxyethylene-b-isoprene-b-oxyethylene) Block Copolymer Aggregates," Journal of Applied Polymer Science, 44:1195-1203 (1992)			
	C51	Scott et al., "Role of Chain Pairing for the Production of Functional Soluble IA Major Histocompatibility Complex Class II Molecules," J. Exp. Med., 183:2087-2095 (1996)			
	C52	Service, R.F., "Dendrimers: Dream Molecules Approach Real Applications," Science, 267:458-459 (1995)			
-	C53	Sharma, S.D. et al., "Antigen-Specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes," Proc. Natl. Acad. Sci. USA, 88:11465-11469 (1991)			
EXAMIN	ER	DATE CONSIDERED			

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999 G

GROUP: 1646

		OTHER ART, JOURNAL ARTICLES, ETC.			
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)				
	C54	Singh et al., "Starburst Dendrimers: Enhanced Performance and Flexiblity for Immunoassays" Clin. Chem. 40/9, 1845-1849 (1194)			
	C55	Stern et al., "The Human class II MHC Protein HLA-DR1 Assembles as Empty αβ Heterodimers in the absence of Antigenic Peptide," Cell, 68:465-477 (1992)			
	C56	Stinson, S.C., "Delving into Dendrimers," C&EN, pp. 28-30, September 22, 1997			
	C57	Strominger et al., "The Class I and Class II Proteins of the Human Major Histocompatibility Complex," JAMA, 274(13):1074-1076 (1995)			
	C58	Shieh et al., "Erosion of a new family of biodegradable polyanhydrides," Journal of Biomedical Materials Research, 28:1465-1475 (1994)			
	C59	Tomalia, D.A., "Starburst/Cascade Dendrimers: Fundamental Building Blocks for a New Nanoscopic Chemistry Set," Aldrichimica Acta, 26(4):91-101 (1993)			
	C60	Tomalia et al., "Starburst Dendrimers: Molecular-Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter," Angew. Chem. Int. Ed. Engl., 29:138-175 (1990)			
	C61	Tomalia et al., "What promise for dendrimers?," Nature, 372:617-618 (1994)			
	C62	Travers, P. et al., "Engineering of soluble MHC class II antigens," Protein Engineering, 3(4):391 (1990)			
	C63	Van Hest et al., "Polystyrene-Dendrimer Amphiphilic Block Copolymers with a Generation-Dependent Aggregation," Science, 268:1592-1595 (1995)			
	C64	Van Straaten, F. et al., "Complete nucleotide sequence of a human c-onc gene: Deduced amino acid sequence of the human c-fos protein," Proc. Natl. acad. Sci. USA, 80:3183-3187 (1983)			
	C65	Viguier, M., "Murine Xenogeneic T Cell Response Against Cellular and soluble Human MHC Class II Antigen," Human Immunology, 14(2):106-107 (1985)			
	C66	Vogt et al., "Ligand Motifs of HLA-DRB5 0101 and DRB1 1501 Molecules Delineated from Self-Peptides," The Journal of Immunology, 153(4):pp. 1665-1673 (1994)			
	C67	Wallny et al., "Soluble mouse major histocompatibility complex class II molecules produced in Drosophila cells," Eur. J. Immunol., 25:1262-1266 (1995)			
	C68	Weber et al., "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor," Nature, 356:793-796 (1992)			
EXAMIN	ER	DATE CONSIDERED			

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: HAR-005

APPLICANT(S): Wucherpfennig et al.

SERIAL NO.: 09/248,964

FILING DATE: February 12, 1999 GR

GROUP: 1646

OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. C69 Wettstein et al., "Expression of a Class II Major Histocompatibility Complex (MHC) Heterodimer in a Lipid-linked Form with Enhanced Peptide/Soluble MHC complex Formation at low pH," J. Exp. Med., 174:219-228 (1991) C70 Wilson et al., "Structural analysis of MHC class I molecules with bound peptide antigens," Seminars in Immunology, 5:75-80 (1993) C71 Wu et al., "Metal-Chelate-Dendrimer-Antibody Constructs for Use in Radioimmunotherapy and Imaging," Bioorganic & Medicinal Chemistry Letters, 4(3):449-454 (1994) C72 Wucherpfennig, K.W. et al., "Molecular Mimicry in T Cell-Mediated Autoimmunity: Viral Peptides Activate Human T Cell Clones Specific for Myelin Basic Protein," Cell, 80:695-705 (1995) C73 Wucherpfennig et al., "Selective Binding of Self Peptides to Disease-associated Major Histocompatibility Complex (MHC) Molecules: A Mechanism for MHC-linked Susceptibility to Human Autoimmune Diseases," J. Exp. Med., 181:1597-1601 (1995) C74 Wucherpfennig et al., "Structural Requirements for binding of an Immunodominant Myelin Basic Protein Peptide to DR2 Isotypes and for Its Recognition by Human T Cell Clones," J. Exp. Med., 179:279-190 (1994)C75 Wucherpfennig et al., "Peptide Independent Assembly of HLA-DR2 Molecules from Subunits Expressed in E. Coli," Journal of Neuroimmunology, Vol. 54, p 206 (1994). C76 Young et al., "Structural studies of class I major histocompatibility complex proteins: insights into antigen presentation," The FASEB Journal, 9:26-36 (1995) C77 Zimmerman et al., "Self-Assembling Dendrimers," Science, 271:1095-1098 (1996) **EXAMINER** DATE CONSIDERED

BRESNAHA6615/8.A842061_1